Sanofi's multiple myeloma drug Sarclisa has much ground to make up on Johnson & Johnson's blockbuster Darzalex but the French major will be hoping that new data in newly diagnosed transplant-eligible patients will help bridge the gap.
The company has highlighted positive data from the Phase III HD7 trial, conducted by the German-Speaking Myeloma Multicenter Group (GMMG)...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

